INAB vs. INKT, ACHL, TARA, PLUR, CYTH, ENLV, NKGN, TVGN, AIM, and ESLA
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), Pluri (PLUR), Cyclo Therapeutics (CYTH), Enlivex Therapeutics (ENLV), NKGen Biotech (NKGN), Tevogen Bio (TVGN), AIM ImmunoTech (AIM), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector.
IN8bio (NASDAQ:INAB) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
In the previous week, IN8bio had 5 more articles in the media than MiNK Therapeutics. MarketBeat recorded 6 mentions for IN8bio and 1 mentions for MiNK Therapeutics. IN8bio's average media sentiment score of 0.71 beat MiNK Therapeutics' score of 0.00 indicating that IN8bio is being referred to more favorably in the media.
MiNK Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
MiNK Therapeutics' return on equity of 0.00% beat IN8bio's return on equity.
IN8bio has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.
92.1% of IN8bio shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 33.0% of IN8bio shares are held by insiders. Comparatively, 17.8% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
IN8bio currently has a consensus price target of $10.75, indicating a potential upside of 953.92%. MiNK Therapeutics has a consensus price target of $9.00, indicating a potential upside of 934.48%. Given IN8bio's higher probable upside, research analysts plainly believe IN8bio is more favorable than MiNK Therapeutics.
IN8bio received 9 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave IN8bio an outperform vote while only 66.67% of users gave MiNK Therapeutics an outperform vote.
Summary
IN8bio beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
